Acinetobacter lysins

Patent metadata

Field	Value
Publication number	US-11180744-B2
Application number	US-201916454045-A
Country	US
Kind code	B2
Filing date	Jun 26, 2019
Priority date	Jun 26, 2014
Publication date	Nov 23, 2021
Grant date	Nov 23, 2021

Abstract

Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acintobacter lysin polypeptides.

First claim

What is claimed is:

1. A method for treating a subject in need thereof, comprising:
administering to the subject with a bacterial infection a composition comprising a polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:20, or SEQ ID NO:21,
wherein the polypeptide is conjugated to an antimicrobial peptide having the amino acid sequence of SEQ ID NO:44 to yield a conjugated polypeptide;
and the conjugated polypeptide has antibacterial activity; and the composition further comprises a pharmaceutically acceptable carrier, buffering agent, or preservative.

2. The method according to claim 1 , wherein the C-terminus of the polypeptide is conjugated to the antimicrobial peptide or the N-terminus of the polypeptide is conjugated to the antimicrobial peptide.

3. The method according to claim 1 , wherein the subject has a bacterial infection and the conjugated polypeptide has antibacterial activity against a gram negative bacterium.

4. The method according to claim 3 , wherein the gram negative bacterium is E.coli, K pneumonia, P. aeruginosa or A. baumannii.

5. The method according to claim 1 , wherein the subject has a surgical wound, wherein the subject is treated by irrigating the surgical wound with the composition.

6. The method according to claim 5 , wherein the surgical wound is irrigated prior to surgical closure of the wound.

7. The method according to claim 1 , wherein the composition is administered topically, subcutaneously, by intravenous injection or orally.

8. The method according to claim 1 , wherein the composition is in the form of a cream, ointment, salve, gel, lozenge, spray, or aerosol.

9. The method for treating a bacterial infection of claim 3 , comprising inhibiting the formation of, or disrupting, a bacterial biofilm comprising administering to a subject in need thereof, the composition, in an amount effective to kill bacteria in the biofilm.

10. The method according to claim 3 , wherein the conjugated polypeptide has antibacterial activity against a gram negative bacterium, and the gram negative bacterium is of the genus Acinetobacter.

11. A method for treating a subject in need thereof, comprising:
administering to the subject with a bacterial infection a composition comprising a polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:1, or SEQ ID NO:21, or a fragment of the polypeptide consisting of the amino acids sequence of SEQ ID NO:43 and the polypeptide or the fragment is conjugated to an antimicrobial peptide having the amino acid sequence SQSRESQC (SEQ ID NO:44) to yield a conjugated polypeptide and the conjugated polypeptide has antibacterial activity; and the composition further comprises a pharmaceutically acceptable carrier, buffering agent, or preservative.

12. The method of claim 11 , wherein the fragment of the polypeptide consisting of the amino acids of SEQ ID NO:43 is conjugated to an antimicrobial peptide having the amino acid sequence SQSRESQC (SEQ ID NO:44) to yield a conjugated polypeptide and the conjugated polypeptide has antibacterial activity.

13. The method according to claim 12 , wherein the subject has a bacterial infection and the conjugated fragment has antibacterial activity against a gram negative bacterium.

14. The method according to claim 13 , wherein the conjugated polypeptide has antibacterial activity against a gram negative bacterium, and the gram negative bacterium is of the genus Acinetobacter.

15. The method according to claim 13 , wherein the gram negative bacterium is E.coli, K pneumonia, P. aeruginosa or A. baumannii.

16. The method according to claim 12 , wherein the bacterial infection is non-responsive to other treatment modalities.

17. The method according to claim 12 , wherein the subject has a surgical wound, wherein the subject is treated by irrigating the surgical wound with the composition.

18. The method according to claim 17 , wherein the surgical wound is irrigated prior to surgical closure of the wound.

19. The method according to claim 12 , wherein the composition is administered topically, subcutaneously, by intravenous injection or orally.

20. The method for treating a bacterial infection of claim 12 , comprising inhibiting the formation of, or disrupting, a bacterial biofilm comprising administering to a subject in need thereof, the composition in an amount effective to kill bacteria in the biofilm.

Assignees

• Univ Rockefeller

Inventors

• Fischetti Vincent
• Schuch Raymond
• Lood Rolf
• Winer Benjamin

Classifications

• A61L2103/15

  Laboratory, medical or dentistry appliances, e.g. catheters or sharps · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K38/162

  from virus · CPC title